Clinical Trials
10 trialsNCT03601442 2026-04-23
Managed Access Programs for CTL019, Tisagenlecleucel
Novartis
Available
NCT05918913 2025-09-05
Expanded Access Program for Revumenib
Syndax Pharmaceuticals
No longer available
NCT03145545 2025-05-22
Expanded Access Protocol Using Alpha/Beta T and CD19+ Depleted PBSC
Children's Hospital of Philadelphia
Available
NCT03594162 2021-12-03
Compassionate Use of CAR T Cells Targeting the CD19 Antigen and Containing the Inducible Caspase 9 Safety Switch
UNC Lineberger Comprehensive Cancer Center
No longer available
NCT01200017 2021-05-27
Expanded Access Protocol (EAP) Using the CliniMACS® Device for Pediatric Haplocompatible Donor Stem Cell Transplant
University of California, San Francisco
No longer available
NCT03501615 2020-06-29
MOXE
AstraZeneca
Approved for marketing
NCT03114228 2019-10-15
An Expanded Treatment Protocol (ETP) of Midostaurin (PKC412) in Patients 18 Years of Age or Older With Newly-diagnosed FLT3-mutated Acute Myeloid Leukemia (AML)
Novartis
No longer available
NCT00423826 2016-02-29
Umbilical Cord Blood Stem Cell Transplant in Treating Patients With Hematologic Cancer or Other Disease
Barbara Ann Karmanos Cancer Institute
No longer available
NCT00481559 2014-01-17
Treatment Protocol of Voraxaze for Patients Experiencing or at Risk of Methotrexate Toxicity
BTG International Inc.
Approved for marketing
NCT01549548 2013-03-15
Compassionate Use Ponatinib
OHSU Knight Cancer Institute
No longer available